Clinical trials: Adjuvant Drug Therapy
NK Cell, B-cell Lymphoma Recurrent
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine.
- Conditions
- NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- NCT05909098
- Testing
- autologous NK cell
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xiangyang No.1 People's Hospital
Head and Neck Cancer
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00336947
- Testing
- tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy
- Where
- 48 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Yokohama City University
Incidental Gallbladder Carcinoma, Biliary Tract Cancer
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma…
- Trial name
- GAIN (NCT03673072)
- Testing
- Gemcitabine, Cisplatin, Oncologically radical margin-free (R0) resection
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Krankenhaus Nordwest
Triple Negative Breast Neoplasms, Triple Negative Breast Cancer
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast…
- Conditions
- Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer
- Trial name
- NCT05485766
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Okayama University
Breast Cancer, Quality of Life
Pharmacist's Influence on Breast Cancer Patient Quality of Life
The purpose of this study is to investigate the impact of pharmacist behavioral intervention's influence on breast cancer patients' quality of life. Croatian randomized controlled trial.
- Trial name
- PIBC (NCT02746666)
- Testing
- Pharmacist's behavioral intervention
- Volunteers
- 70 people
- Sponsor
- University Hospital Sestre Milosrdnice
Ovarian Carcinoma
HE4 as a Relapse Biomarker in Ovarian Cancers
HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of serum HE4 before surgery has been demonstrated to predict overall survival and its interest has also been shown in combination with…
- Trial name
- PRONOV4IR (NCT02595281)
- Testing
- Experimental arm
- Where
- 7 sites in France
- Volunteers
- 90 people
- Sponsor
- Institut de Cancérologie de Lorraine
Ovarian Cancer
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002477
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Adjuvant Therapy
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the…
- Trial name
- SENIOR (NCT07005557)
- Testing
- Chemotherapy, CDK4/6 Inhibitor, Endocrine therapy
- Volunteers
- 1,244 people
- Sponsor
- Fudan University
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection.
- Trial name
- NCT06761846
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Status Asthmaticus
The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
The purpose of this investigation is to perform a pilot study assessing the safety and utility of intravenous ketamine as an adjuvant therapy in the emergency department setting for pediatric patients in acute status asthmaticus…
- Trial name
- NCT03338205
- Testing
- Ketamine
- Sponsor
- Augusta University
Oncology, Breast Cancer
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.
- Conditions
- Oncology, Breast Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- PantoCIN (NCT03948477)
- Testing
- Pantoprazole 40mg
- Where
- 10 sites in New Zealand
- Volunteers
- 160 people
- Sponsor
- University of Auckland, New Zealand
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005581
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Where
- 25 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Gastric Cancer
Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1
S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients. Recently, some case and small-sized studies have been reported on lacrimal drainage obstruction(LDO)caused by…
- Trial name
- NCT01621919
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Bundang Hospital
Nasopharyngeal Neoplasms
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to determine whether Intensity-modulated radiation therapy (IMRT) combined inductive and concurrent chemotherapy with more intensive regimen (cisplatin and paclitaxel) is feasible and effective than…
- Trial name
- NCT01797900
- Testing
- Cisplatin, Paclitaxel, IMRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Breast Neoplasm
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
The purpose of this study is to compare the incidence of cardiac dysfunction in subjects with human epidermal growth factor receptor 2 (HER2) positive breast cancer treated with either doxorubicin or pegylated liposomal…
- Trial name
- NCT00550771
- Testing
- doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, PLD, cyclophosphamide, trastuzumab, paclitaxel
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, epirubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516425
- Testing
- pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Charing Cross Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.